Recognizing the potential for higher therapeutic efficacy by targeting both cancer cells and the bone marrow niche, we examined whether targeting HDAC3 in BMSCs could enhance the anti-AML effects of venetoclax. The gene discussed is HDAC3; the disease is acute myeloid leukemia.